AU658271B2 — Butadiene derivatives and process for preparing the same
Assigned to Tanabe Pharma Corp · Expires 1995-04-06 · 31y expired
What this patent protects
Novel butadiene derivatives of the formula [I]: <CHEM> wherein Ring A is tri-lower alkoxyphenyl, R<1> and R<2> combine each other to form a group of the formula: &rdurule& N-R<3> or one of R<1> and R<2> is lower alkoxy, and the ot…
USPTO Abstract
Novel butadiene derivatives of the formula [I]: <CHEM> wherein Ring A is tri-lower alkoxyphenyl, R<1> and R<2> combine each other to form a group of the formula: &rdurule& N-R<3> or one of R<1> and R<2> is lower alkoxy, and the other is group of the formula: -NHR<3>, in which R<3> is hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted amino, hydroxy or pyridylcarbonyl, or salts thereof. Among the desired butadiene derivatives [I] of the present invention, the 3-butenoic acid-type compounds per se have antithrombotic activity, but they can also be used as an intermediate for preparing the 2,5-pyrrolidinedione-type compounds having excellent antithrombotic activity. And additionally a butenoic acid ester of the formula [II]: <CHEM> wherein Ring A is a tri-lower alkoxyphenyl group, and one of R<1><2> and R<2><2> is a lower alkoxy group, and the other is hydroxy group, or a salt thereof, as synthetic intermediate.
Drugs covered by this patent
- OxyContin (oxycodone) · Purdue Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.